Methods for treating rheumatoid arthritis using human antibodies that bind human TNFα
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
1. A method for treating a subject suffering from rheumatoid arthritis, comprising administering to the subject both an antibody and methotrexate, such that the rheumatoid arthritis is treated, wherein the antibody is an isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNFα with a K d of 1×10 −8 M or less and a K off rate constant of 1×10 −3 s −1 or less, both determined by surface plasmon resonance, neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC 50 of 1×10 −7 M or less, and neutralizes TNFα-induced cellular activation in a standard in vitro assay for TNRα-induced ELAM-1 expression on human umbilical vein endothelial cells (HUVEC).
2. The method of claim 1 , wherein the isolated human antibody, or antigen-binding portion thereof, dissociates from human TNFα with a K off rate constant of 5×10 −4 s −1 or less.
3. The method of claim 1 , wherein the isolated human antibody, or antigen-binding portion thereof, dissociates from human TNFα with a K off rate constant of 1 ×10 − s −1 or less.
4. The method of claim 1 , wherein the isolated human antibody, or antigen-binding portion thereof, neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC 50 of 1×10 −8 M or less.
5. The method of claim 1 , wherein the isolated human antibody, or antigen-binding portion thereof, neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC 50 of 1×10 −9 M or less.
6. The method of claim 1 , wherein the isolated human antibody, or antigen-binding portion thereof, neutralizes human TNFα cytotoxicity in a standard in vitro L929 assay with an IC 50 of 1×10 −10 M or less.
7. The method of claim 1 , wherein the isolated human antibody, or antigen-binding portion thereof, is a recombinant antibody, or antigen-binding portion thereof.
8. A method for treating a subject suffering from rheumatoid arthritis, comprising administering to the subject both an antibody and methotrexate, such that the rheumatoid arthritis is treated, wherein the antibody is an isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNFα with a K d of 1×10 −8 M or less and a K off rate constant of 1×10 −3 s −1 or less, both determined by surface plasmon resonance, and neutralizes TNFα-induced cellular activation in a standard in vitro assay for TNFα-induced ELAM-1 expression on human umbilical vein endothelial cells (HUVEC).
9. The method of claim 8 , wherein the isolated human antibody, or antigen-binding portion thereof, dissociates from human TNFα with a K off rate constant of 5×10 −4 s −1 or less.
10. The method of claim 8 , wherein the isolated human antibody, or antigen-binding portion thereof, dissociates from human TNFα with a K off rate constant of 1×10 −4 s −1 or less.
11. The method of claim 8 , wherein the isolated human antibody, or antigen-binding portion thereof, is a recombinant antibody, or antigen-binding portion thereof.